Cagrilintide registration compares two formulations given weekly for 5 weeks in adults with excess weight
A ClinicalTrials.gov registration describes a randomized comparison of two cagrilintide versions, B and D, each given as a once-weekly subcutaneous injection for 5 weeks, with participation lasting about 14 weeks.
2026 · Trial registration · n=50 · Human · Published October 10, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the registration says
This is a trial registration in humans, describing a study in people living with excess body weight; the provided registration excerpt does not state how many participants were enrolled. The record states that the purpose is to compare two different versions of cagrilintide and see how these work in that population.
The registration states that each participant will get either cagrilintide B or cagrilintide D injections, and that which treatment a participant receives is decided by chance. Total participation is described as lasting about 14 weeks.
How the arms are described
Two arms are listed, both labeled experimental. In one, participants receive cagrilintide B subcutaneously once weekly for 5 weeks; in the other, participants receive cagrilintide D subcutaneously once weekly for 5 weeks. The interventions section repeats that both versions are administered subcutaneously.
The excerpt does not list outcome measures, eligibility criteria, or any results. It is a description of planned or conducted study activity, not a report of findings.
Reported dosing
The registration describes timing and route but no milligram amounts. Participants assigned to cagrilintide B receive it subcutaneously once weekly for 5 weeks, and participants assigned to cagrilintide D receive it subcutaneously once weekly for 5 weeks. No dose strength for either version appears in the excerpt.
Limitations
A registration record is not a results publication. The excerpt reports no outcome data, no safety findings, and no statistical comparison between the two cagrilintide versions, so nothing can be said here about how either version performed.
The excerpt also does not state the number of participants, the study sites, blinding arrangements, eligibility criteria, or funding and sponsor details. The comparison is between two versions of the same compound, with no placebo or active comparator described in the text provided.
Regulatory context
Cagrilintide, also referred to as AM833 or NNC0174-0833 and coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use. That status comes from this site's regulatory review and not from the registration described above.
Study-reported dosing
| Regimen as reported | Population | Route | Source |
|---|---|---|---|
| cagrilintide B subcutaneously once weekly for 5 weeksThe registration excerpt states no milligram amount for this version. | participants assigned to the cagrilintide B arm, described as adults living with excess body weight | Subcutaneous | A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight (2026) Trial registrationHumann=50 |
| cagrilintide D subcutaneously once weekly for 5 weeksThe registration excerpt states no milligram amount for this version. | participants assigned to the cagrilintide D arm, described as adults living with excess body weight | Subcutaneous | A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight (2026) Trial registrationHumann=50 |
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The registration states the study compares two different versions of cagrilintide in people living with excess body weight.
“The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight.”
Assignment to one of the two cagrilintide versions is described as randomized.
“Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance.”
Participation is described as lasting about 14 weeks.
“Participant will be in this clinical study for about 14 weeks.”
The cagrilintide B arm is described as once-weekly subcutaneous dosing for 5 weeks.
“Participants will receive cagrilintide B subcutaneously once weekly for 5 weeks.”
The cagrilintide D arm is described as once-weekly subcutaneous dosing for 5 weeks.
“Participants will receive cagrilintide D subcutaneously once weekly for 5 weeks.”
Common questions
Does this registration report any results?
No. The excerpt describes the purpose, the two arms, and the route and schedule of dosing, but contains no outcome data or safety findings.
Was there a placebo group?
The excerpt lists only two arms, cagrilintide B and cagrilintide D, both labeled experimental. No placebo or other comparator is described.
How were participants assigned to a version?
The registration states that which treatment a participant will get is decided by chance.
How long did participation last?
The registration states participants will be in the study for about 14 weeks, with once-weekly subcutaneous injections over 5 weeks.
Source
- 1.A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight (2026)Trial registrationhumann=50NCT NCT07605052